Skyrizi is used to treat certain inflammatory conditions, such as plaque psoriasis. The drug starts working after your first dose. Skyrizi is approved by the Food and Drug Administration (FDA) to ...

Drug maker AbbVie Inc. on Tuesday said the Food and Drug Administration had approved its drug Skyrizi for adults with moderate to severe forms of ulcerative colitis, broadening the company’s ...

AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final monthly ranking of the biggest TV ad spenders in biopharma.

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

AbbVie’s hotly anticipated psoriasis drug Skyrizi (risankizumab) has been approved in Japan, the first country to okay this potential blockbuster. Skyrizi is important for AbbVie as sales of its ...

Skyrizi was the top Rx and over-the-counter (OTC) pharma brand advertising on TV in 2024, according to data released by iSpot.tv on Thursday afternoon. AbbVie’s psoriasis, ulcerative colitis, Crohn’s ...

This week also saw a notable surge from pharmaceutical company AbbVie, with their drug Skyrizi, which leaped from 32nd to 4th place. PayPal, T-Mobile, and Vicks also made solid showings ...